絞り込み

17057

広告

BPS804 Anti-sclerostin Antibody in Adults with Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial.

著者 Glorieux FH , Devogelaer JP , Durigova M , Goemaere S , Hemsley S , Jakob F , Junker U , Ruckle J , Seefried L , Winkle PJ
J Bone Miner Res.2017 Mar 29 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (3view , 0users)

Full Text Sources

Medical

This 21-week, open-label, phase 2a trial aimed to evaluate the pharmacodynamics and safety of multiple, escalating infusions of BPS804, a neutralizing, anti-sclerostin antibody, in adults with moderate osteogenesis imperfecta (OI).
PMID: 28370407 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード